Biomarkers of response to advanced prostate cancer therapy

Roberto Iacovelli, Chiara Ciccarese, Giovanni Schinzari, Ernesto Rossi, Brigida Anna Maiorano, Serena Astore, Tatiana D’Angelo, Antonella Cannella, Celeste Pirozzoli, Maria Anna Teberino, Francesco Pierconti, Maurizio Martini, Giampaolo Tortora

Research output: Contribution to journalReview articlepeer-review


Introduction: Prostate cancer (PCa) is one of the most common adult malignancies worldwide, and a major leading cause of cancer-related death in men in Western societies. In the last years, the prognosis of advanced PCa patients has been impressively improved thanks to the development of different therapeutic agents, including taxanes (docetaxel and cabazitaxel), second-generation anti-hormonal agents (abiraterone and enzalutamide), and the radiopharmaceutical Radium-223. However, great efforts are still needed to properly select the most appropriate treatment for each single patient. Areas covered: Several prognostic or predictive biomarkers have been studied, none of which has an established validated role in daily clinical practice. This paper analyzed the major biomarkers (including PSA, androgen receptor (AR) splice variants, βIII-tubulin, ALP, circulating tumor cells, and DNA repair genes) with a potential prognostic and/or predictive role in advanced PCa patients. Expert commentary: Surrogate biomarkers–measurable, reproducible, closely associated with tumor behavior and linked to relevant clinical outcomes–are urgently needed to improve PCa patient management.

Original languageEnglish
Pages (from-to)195-205
Number of pages11
JournalExpert Review of Molecular Diagnostics
Issue number2
Publication statusPublished - Feb 1 2020


  • AR-V7
  • biomarker
  • DRGs
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Biomarkers of response to advanced prostate cancer therapy'. Together they form a unique fingerprint.

Cite this